Covid, Sanofi-Gsk vaccine “in the second half of 2021. Planning is needed”

Influenza, from general practitioners is boom 'reservations' vaccines

“Getting a vaccine, or as we all hope to more than one vaccine, able to protect the world population, European and Italian from Covid-19” is not the only goal that is important to Big Pharma. When one or more shield products are available, “a perfect organization will also be needed from the point of view of identifying the categories to which it is dispensed as a priority, distribution and organization of administration”. As for the anti-flu campaigns, also for the future anti-Sars-CoV-2 prophylaxis the watchword is “programming” according to Mario Merlo, general manager for Italy of Sanofi Pasteur, Vaccines division of the French Sanofi. “We need to plan everything now,” he warned in an interview with Adnkronos Salute.

© Provided by Adnkronos

The vaccine challenge also sees Sanofi at the forefront: together with the British GlaxoSmithKline (Gsk) it is developing an adjuvant product for the prevention of the new coronavirus, expected “in the second half of 2021”. The two companies have already signed a contract with the European Commission that will allow Member States to purchase up to 300 million doses and “just tomorrow – recalls the manager – with the highest authorities we will inaugurate at the Anagni plant”, in the province of Frosinone. , “the Covid vaccine filling production line to support clinical phase I / II studies that are currently underway”.

“The vaccine is a race against time which however – Merlo warns – cannot and must not go to the detriment of safety and quality. During the production of a vaccine, for example the flu, 70% of the time is invested in quality control. “and this priority must also apply in the war against Covid.

“When the phase I / II studies underway and those phase III that will start by the end of the year are successful, if the interviews with the regulatory agencies are also successful, we expect a Sanofi-Gsk vaccine no earlier than the second half of 2021 “, estimates the GM of Sanofi Pasteur in Italy, which insists:” Billions of doses will be needed and adequate planning must be considered inevitable “. A plan to be agreed “together” among all the players in the field. Because “no one wins this battle alone – concludes Merlo – We need alliances, we need to rewrite a chapter on the subject of public health and health. And health is the most important investment”.


Please enter your comment!
Please enter your name here